Content about Actavis

October 22, 2012

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

October 16, 2012

The Federal Trade Commission has voted to approve Watson Pharmaceutical's acquisition of Switzerland-based generic drug maker Actavis.

October 16, 2012

Par Pharmaceutical Cos. has entered into agreements with Watson Pharmaceuticals and Actavis to purchase five generic products currently marketed in the United States by Watson or Actavis, eight abbreviated new drug applications currently awaiting regulatory approval, and a generic product in late-stage development.

October 10, 2012

The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

October 8, 2012

European regulators have approved U.S. drug maker Watson's acquisition of Switzerland-based Actavis, Watson said.

September 18, 2012

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


July 17, 2012

Watson Pharmaceuticals confirmed it received a request for additional information from the Federal Trade Commission in connection with the drug maker's pending acquisition of Actavis Group.

July 5, 2012

Actavis has received a preliminary approval for a generic drug for treating high blood pressure, the drug maker said Thursday.

June 25, 2012

The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.

May 31, 2012

Actavis has launched a generic drug for high blood pressure and chest pain, the company said.

May 18, 2012

The Food and Drug Administration has approved a treatment for Parkinson's disease made by Actavis, the drug maker said Friday.

May 16, 2012

Watson has announced its intention to acquire Actavis, the company said. Following news reports that the U.S.-based generic drug maker would acquire Switzerland-based Actavis, Watson announced that it would buy the latter for $5.6 billion.

May 10, 2012

Generic drug maker Watson Pharmaceuticals has formed a special office to handle its pending acquisition of Actavis, the company said.

April 26, 2012

Watson has announced its intention to acquire Actavis, the company said.

April 24, 2012

Watson Pharmaceuticals is buying Actavis Group for $5.9 billion, according to published reports.

March 21, 2012

Watson Pharmaceuticals is looking to acquire Actavis, according to published reports.

February 23, 2012

The president of one of the world's largest generic drug manufacturers will serve as chairman of the Generic Pharmaceutical Association, the organization said Thursday.

February 21, 2012

A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

February 9, 2012

Social media strategist Robin Leedy & Associates, a public relations and social media marketing agency, on Wednesday announced the signing of six clients featuring several brands in the health and beauty space.

January 30, 2012

Iceland-based drug maker Actavis and Poland-based Bioton have formed a partnership that they said would "shake up" the diabetes market.

January 23, 2012

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said.

January 4, 2012

The Food and Drug Administration has approved a generic version of a drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Wednesday.

January 3, 2012

Actavis has begun shipping clobetasol propionate shampoo and clobetasol propionate lotion, which were granted 180-day marketing exclusivity by the Food and Drug Administration.

December 22, 2011

Drug maker Actavis is partnering with QRxPharma to sell what the former called a novel pain drug in the United States.

© 2014 Drug Store News. All Rights Reserved.